Tags

Type your tag names separated by a space and hit enter

Different angiogenic CXC chemokine levels in bronchoalveolar lavage fluid after interferon gamma-1b therapy in idiopathic pulmonary fibrosis patients.
Pulm Pharmacol Ther. 2008 Dec; 21(6):840-4.PP

Abstract

BACKGROUND AND AIM

Pulmonary fibrosis is a devastating disease with few treatment options. Angiogenesis that leads to aberrant vascular remodeling is regulated by an opposing balance of angiogenic and angiostatic factors. The present study aims to evaluate the role of three angiogenic (IL-8, ENA-78 and GRO-a) and three angiostatic (MIG, IP-10, ITAC) chemokines in bronchoalveolar lavage fluid (BALF), before and after treatment with Interferon gamma-1b (IFN gamma-1b).

PATIENTS AND METHODS

We studied prospectively 20 patients (16 males, 4 females) of median age 68 years (range, 40-75) with histologically confirmed IPF/UIP. Patients were assigned to receive IFN gamma-1b 200 microg sc thrice a week. Angiogenic and angiostatic mediators' levels were measured by ELISA kits.

RESULTS

The levels of the angiogenic chemokines significantly decreased after 12 months (mo) of IFN-gamma-1b treatment (median values in pg/ml, IL-8/CXCL8: 640 vs. 81, p<0.05, ENA-78/CXCL5: 191 vs. 51, p<0.005 and GRO-alpha: 1827 vs. 710, p<0.005). No significant differences were detected in the levels of the angiostatic chemokines after therapy (median values in pg/ml, IP-10/CXCL10: 56 vs. 56.5, p=0.6, ITAC/CXCL11: 43 vs. 47, p=0.11). However, a significant decrease in the MIG/CXCL9: 66 vs. 31, p=0.006, has been detected.

CONCLUSION

These findings support the notion that IFN gamma may be one of the important mediators regulating angiogenetic balance in IPF. However, IFN gamma-1b decreases MIG levels, finding that in association with no alteration in IP-10 and I-TAC levels, could explain in part the nonbeneficial effect of this drug in IPF.

Authors+Show Affiliations

Department of Thoracic Medicine, University General Hospital, Medical School, University of Crete, Heraklion, 71110 Crete, Greece.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article

Language

eng

PubMed ID

18644457

Citation

Antoniou, Katerina M., et al. "Different Angiogenic CXC Chemokine Levels in Bronchoalveolar Lavage Fluid After Interferon Gamma-1b Therapy in Idiopathic Pulmonary Fibrosis Patients." Pulmonary Pharmacology & Therapeutics, vol. 21, no. 6, 2008, pp. 840-4.
Antoniou KM, Tzanakis N, Tzortzaki EG, et al. Different angiogenic CXC chemokine levels in bronchoalveolar lavage fluid after interferon gamma-1b therapy in idiopathic pulmonary fibrosis patients. Pulm Pharmacol Ther. 2008;21(6):840-4.
Antoniou, K. M., Tzanakis, N., Tzortzaki, E. G., Malagari, K., Koutsopoulos, A. V., Alexandrakis, M., Wells, A. U., & Siafakas, N. M. (2008). Different angiogenic CXC chemokine levels in bronchoalveolar lavage fluid after interferon gamma-1b therapy in idiopathic pulmonary fibrosis patients. Pulmonary Pharmacology & Therapeutics, 21(6), 840-4. https://doi.org/10.1016/j.pupt.2008.06.005
Antoniou KM, et al. Different Angiogenic CXC Chemokine Levels in Bronchoalveolar Lavage Fluid After Interferon Gamma-1b Therapy in Idiopathic Pulmonary Fibrosis Patients. Pulm Pharmacol Ther. 2008;21(6):840-4. PubMed PMID: 18644457.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Different angiogenic CXC chemokine levels in bronchoalveolar lavage fluid after interferon gamma-1b therapy in idiopathic pulmonary fibrosis patients. AU - Antoniou,Katerina M, AU - Tzanakis,Nikolaos, AU - Tzortzaki,Eleni G, AU - Malagari,Katerina, AU - Koutsopoulos,Anastassios V, AU - Alexandrakis,Michael, AU - Wells,Athol U, AU - Siafakas,Nikolaos M, Y1 - 2008/07/02/ PY - 2007/07/14/received PY - 2008/06/24/revised PY - 2008/06/30/accepted PY - 2008/7/23/pubmed PY - 2009/5/23/medline PY - 2008/7/23/entrez SP - 840 EP - 4 JF - Pulmonary pharmacology & therapeutics JO - Pulm Pharmacol Ther VL - 21 IS - 6 N2 - BACKGROUND AND AIM: Pulmonary fibrosis is a devastating disease with few treatment options. Angiogenesis that leads to aberrant vascular remodeling is regulated by an opposing balance of angiogenic and angiostatic factors. The present study aims to evaluate the role of three angiogenic (IL-8, ENA-78 and GRO-a) and three angiostatic (MIG, IP-10, ITAC) chemokines in bronchoalveolar lavage fluid (BALF), before and after treatment with Interferon gamma-1b (IFN gamma-1b). PATIENTS AND METHODS: We studied prospectively 20 patients (16 males, 4 females) of median age 68 years (range, 40-75) with histologically confirmed IPF/UIP. Patients were assigned to receive IFN gamma-1b 200 microg sc thrice a week. Angiogenic and angiostatic mediators' levels were measured by ELISA kits. RESULTS: The levels of the angiogenic chemokines significantly decreased after 12 months (mo) of IFN-gamma-1b treatment (median values in pg/ml, IL-8/CXCL8: 640 vs. 81, p<0.05, ENA-78/CXCL5: 191 vs. 51, p<0.005 and GRO-alpha: 1827 vs. 710, p<0.005). No significant differences were detected in the levels of the angiostatic chemokines after therapy (median values in pg/ml, IP-10/CXCL10: 56 vs. 56.5, p=0.6, ITAC/CXCL11: 43 vs. 47, p=0.11). However, a significant decrease in the MIG/CXCL9: 66 vs. 31, p=0.006, has been detected. CONCLUSION: These findings support the notion that IFN gamma may be one of the important mediators regulating angiogenetic balance in IPF. However, IFN gamma-1b decreases MIG levels, finding that in association with no alteration in IP-10 and I-TAC levels, could explain in part the nonbeneficial effect of this drug in IPF. SN - 1094-5539 UR - https://www.unboundmedicine.com/medline/citation/18644457/Different_angiogenic_CXC_chemokine_levels_in_bronchoalveolar_lavage_fluid_after_interferon_gamma_1b_therapy_in_idiopathic_pulmonary_fibrosis_patients_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S1094-5539(08)00069-2 DB - PRIME DP - Unbound Medicine ER -